Figure 2
ECP-treated splenocytes reduce CD8+IFN-γ+ effector T cells in vivo. C3H.SW recipient mice received 5.0 × 106 bone marrow and 106 T cells from syngeneic (C3H.SW) or allogeneic (B6-Ly5.2) donors on day 0 followed by infusion of B6→C3H.SW ECP-treated cells on day 7. IFN-γ production by donor CD8+ effector cells was measured 96 hours later. (A) Representative flow cytometry data of unseparated splenocytes gated on whole-cell scatter. Percentage of donor (CD45.1+) CD8+ T cells in R4 (left) or producing IFN-γ (right) indicated. (B) Numbers of donor CD8+IFN-γ+ cells per spleen. ▩ versus ■, *P < .05. Data are means (± SD) pooled from 3 independent experiments (n = 9-20 per group).

ECP-treated splenocytes reduce CD8+IFN-γ+ effector T cells in vivo. C3H.SW recipient mice received 5.0 × 106 bone marrow and 106 T cells from syngeneic (C3H.SW) or allogeneic (B6-Ly5.2) donors on day 0 followed by infusion of B6→C3H.SW ECP-treated cells on day 7. IFN-γ production by donor CD8+ effector cells was measured 96 hours later. (A) Representative flow cytometry data of unseparated splenocytes gated on whole-cell scatter. Percentage of donor (CD45.1+) CD8+ T cells in R4 (left) or producing IFN-γ (right) indicated. (B) Numbers of donor CD8+IFN-γ+ cells per spleen. ▩ versus ■, *P < .05. Data are means (± SD) pooled from 3 independent experiments (n = 9-20 per group).

Close Modal

or Create an Account

Close Modal
Close Modal